CureVac Statistics

Total Valuation

CureVac has a market cap or net worth of EUR 1.05 billion. The enterprise value is 680.83 million.

Market Cap	1.05B
Enterprise Value	680.83M

Important Dates

The next estimated earnings date is Friday, August 15, 2025.

Earnings Date	Aug 15, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	225.17M
Shares Outstanding	n/a
Shares Change (YoY)	+0.20%
Shares Change (QoQ)	+0.31%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	125.87M

Valuation Ratios

The trailing PE ratio is 5.83.

PE Ratio	5.83
Forward PE	n/a
PS Ratio	2.01
PB Ratio	1.63
P/TBV Ratio	1.69
P/FCF Ratio	7.15
P/OCF Ratio	6.71
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 2.98, with an EV/FCF ratio of 4.62.

EV / Earnings	3.77
EV / Sales	1.40
EV / EBITDA	2.98
EV / EBIT	3.21
EV / FCF	4.62

Financial Position

The company has a current ratio of 7.65, with a Debt / Equity ratio of 0.06.

Current Ratio	7.65
Quick Ratio	7.33
Debt / Equity	0.06
Debt / EBITDA	0.15
Debt / FCF	0.25
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is 33.04% and return on invested capital (ROIC) is 24.37%.

Return on Equity (ROE)	33.04%
Return on Assets (ROA)	19.93%
Return on Invested Capital (ROIC)	24.37%
Return on Capital Employed (ROCE)	33.54%
Revenue Per Employee	579,314
Profits Per Employee	199,840
Employee Count	983
Asset Turnover	0.73
Inventory Turnover	4.85

Taxes

In the past 12 months, CureVac has paid 28.46 million in taxes.

Income Tax	28.46M
Effective Tax Rate	13.61%

Stock Price Statistics

The stock price has increased by +44.06% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+44.06%
50-Day Moving Average	3.65
200-Day Moving Average	3.14
Relative Strength Index (RSI)	63.26
Average Volume (20 Days)	108,693

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	3.64

Income Statement

In the last 12 months, CureVac had revenue of EUR 523.70 million and earned 180.66 million in profits. Earnings per share was 0.80.

Revenue	523.70M
Gross Profit	458.88M
Operating Income	228.37M
Pretax Income	209.11M
Net Income	180.66M
EBITDA	240.86M
EBIT	228.37M
Earnings Per Share (EPS)	0.80

Full Income Statement

Balance Sheet

The company has 438.33 million in cash and 37.38 million in debt, giving a net cash position of 400.95 million.

Cash & Cash Equivalents	438.33M
Total Debt	37.38M
Net Cash	400.95M
Net Cash Per Share	n/a
Equity (Book Value)	646.69M
Book Value Per Share	2.87
Working Capital	407.81M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 157.03 million and capital expenditures -9.73 million, giving a free cash flow of 147.31 million.

Operating Cash Flow	157.03M
Capital Expenditures	-9.73M
Free Cash Flow	147.31M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 87.62%, with operating and profit margins of 43.61% and 34.50%.

Gross Margin	87.62%
Operating Margin	43.61%
Pretax Margin	39.93%
Profit Margin	34.50%
EBITDA Margin	45.99%
EBIT Margin	43.61%
FCF Margin	28.13%

Dividends & Yields

CureVac does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.20%
Shareholder Yield	n/a
Earnings Yield	17.15%
FCF Yield	13.98%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

CureVac has an Altman Z-Score of 3.87 and a Piotroski F-Score of 6.

Altman Z-Score	3.87
Piotroski F-Score	6